Skip to content

Scancell Share Price Plunges 6% on £3M Capital Raise

Shares of Scancell Holdings Plc (LON: SCLP) today fell 6% after the cancer treatment company announced that it has raised £3 million through an oversubscribed offer where investors bought new shares at 13p apiece.

The company also announced that it would hold a general meeting on November 5 to allow more shareholders to vote on its £17.9 million convertible loan note injection from Redmile Funds.

Scancell said that proxy votes in support of the deal were in excess of 70% but fell short of the 75% of shareholder votes required to accept the cash injection.

The company’s shares surged 24.7% on October 2 after the company agreed to partner with Cobra Biologics to manufacture plasmid DNA required for use in its COVIDITY Phase 1 clinical trial for its COVID-19 vaccine in 2021.

However, its share price has trended lower since then.

Scancell share price

Tradingview chart of Scancell share price 30102020

Scancell shares today fell 6% to trade at 14p having dropped from yesterday’s closing price of 14.9p.

People who read this also read:

Simon Mugo
Simon Mugo
Contributor

Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.